Crown Holdings (CCK) Declares $0.2 Quarterly Dividend; 0.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Crown Holdings (CCK) PT Raised to $138 at RBC Capital
July 23, 2021 10:50 AM EDTRBC Capital analyst Arun Viswanathan raised the price target on Crown Holdings (NYSE: CCK) to $138.00 (from $136.00) while maintaining an Outperform rating.
The analyst commented, "We are increasing our EBITDA estimates to reflect continued robust beverage can volume growth (sold-out NA position), improving margin profile... More
Crown Holdings (CCK) PT Raised to $130 at BofA Securities
July 21, 2021 5:34 AM EDTBofA Securities analyst George Staphos raised the price target on Crown Holdings (NYSE: CCK) to $130.00 (from $125.00) while maintaining a Buy rating.... More
Pre-Open Stock Movers 07/20: (IMNM) (NURO) (PTON) Higher; (ARDX) (PPG) (RKT) Lower (more...)
July 20, 2021 9:25 AM EDTPre-Open Stock Movers
Ardelyx, Inc. (Nasdaq: ARDX) 73.3% LOWER; received a letter from the U.S. Food and Drug Administration (the "FDA") on July 13, 2021, stating that, as part of its ongoing review of the company's New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic kidney disease ("CKD") on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The letter stated that the notification does not reflect a final decision on the information under review. The... More
